Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Commercial Sponsor
AstraZeneca
Summary
Eligible patients will be randomised to one of three trial Arms. In Arm 1: patients will receive platinum-based chemotherapy in combination with bevacizumab and a durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, a durvalumab placebo (saline IV infusion) and an olaparib placebo (tablets). In Arm 2: patients will receive chemotherapy in combination with bevacizumab and durvalumab, followed by maintenance bevacizumab, durvalumab and an olaparib placebo. In Arm 3: patients will receive chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. In Arm 4: patients will also receive chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib, however in this arm bevacizumab will be optional according to local practice.